Serum Institute of India (SII) today announces it has resumed exports to the international vaccine sharing programme COVAX. SII’s supply of doses via COVAX is expected to increase substantially into first quarter of 2022, Serum Institute said in a press release. SII has reached this milestone ahead of time via rapid expansion of production capacity at its site in Pune” Serum added. Adar Poonawalla, CEO of Serum Institute of India said, “ I want to thank our workforce for their superhuman efforts in achieving this major milestone, with 1 billion doses of COVISHIELD. Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance which leads the COVAX Facility said “The resumption of supplies from Serum Institute of India is an important development for COVAX as it enters its busiest period yet for shipping vaccines to participating economies.

Source: The Hindu November 27, 2021 02:35 UTC